Role of Glutamate Excitotoxicity in Glioblastoma Growth and Its Implications in Treatment
Cell Biology International · 2025
DOI: 10.1002/cbin.70005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Biology International, 2025. Verfasst von Colin Moriarty und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Glioblastoma, Glutamic Acid, Brain Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma is a highly malignant and invasive type of primary brain tumor that originates from astrocytes. Glutamate, a neurotransmitter in the brain plays a crucial role in excitotoxic cell death. Excessive glutamate triggers a pathological process known as glutamate excitotoxicity, leading to neuronal damage. This excitotoxicity contributes to neuronal death and tumor necrosis in glioblastoma, resulting in seizures and symptoms such as difficulty in concentrating, low energy, depression, and insomnia. Glioblastoma cells, derived from astrocytes, fail to maintain glutamate‐glutamine homeostasis, releasing excess glutamate into the extracellular space. This glutamate activates ionotropic N‐methyl‐ D ‐aspartate (NMDA) receptors and α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptors on nearby neurons, causing hyperexcitability and triggering apoptosis through caspase activation. Additionally, glioblastoma cells possess calcium‐permeable AMPA receptors, which are activated by glutamate in an autocrine manner. This activation increases intracellular calcium levels, triggering various signaling pathways. Alkylating agent temozolomide has been used to counteract glutamate excitotoxicity, but its efficacy in directly combating excitotoxicity is limited due to the development of resistance in glioblastoma cells. There is an unmet need for alternative biochemical agents that can have the greatest impact on reducing glutamate excitotoxicity in glioblastoma. In this review, we discuss the mechanism and various signaling pathways involved in glutamate excitotoxicity in glioblastoma cells. We also examine the roles of various receptor and transporter proteins, in glutamate excitotoxicity and highlight biochemical agents that can mitigate glutamate excitotoxicity in glioblastoma and serve as potential therapeutic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Zitieren
APA
Moriarty, C., Gupta, N., & Bhattacharya, D. (2025). Role of Glutamate Excitotoxicity in Glioblastoma Growth and Its Implications in Treatment. Cell Biology International. https://doi.org/10.1002/cbin.70005
Vancouver
Moriarty C, Gupta N, Bhattacharya D. Role of Glutamate Excitotoxicity in Glioblastoma Growth and Its Implications in Treatment. Cell Biology International. 2025. doi:10.1002/cbin.70005
BibTeX
@article{Moriarty2025,
author = {Moriarty, Colin and Gupta, Natasha and Bhattacharya, Debanjan},
title = {Role of Glutamate Excitotoxicity in Glioblastoma Growth and Its Implications in Treatment},
journal = {Cell Biology International},
year = {2025},
doi = {10.1002/cbin.70005}
}
EUVIMED